30 results about "Etamsylate" patented technology

Taught is a composition for enhancing potency and / or for prolonging the duration of action of an anesthetic comprising dexamethasone, compound vitamin B, metronidazole, berberine, etamsylate, gentamicin, chymotrypsin, methylene blue trihydrate, and 5% sodium bicarbonate aq. When administered with an anesthetic, the composition shortens the onset time of the anesthetic, and prolongs the duration of anesthesia.

The invention discloses a method for producing high-purity etamsylate. The method comprises the following steps: carrying out a sulfonation reaction on hydroquinone serving as an initial material, a sulfonating agent, a dispersing agent and an organic solvent to obtain 2,5-dihydroxybenzenesulfonic acid; cooling the reaction solution to 45-70 DEG C, adding a mixed solution of diethylamine and waterto form a salt, cooling and crystallizing, so as to obtain the etamsylate. According to the reaction system used in the method, the fluidity of the system is improved, and the three-transfer-one-reaction efficiency is improved, so that the conversion rate of the materials is improved by 5-10%; when the system is cooled to 45-70 DEG C after the reaction is ended, the mixed solution of diethylamineand water is directly added into the system, the operation is simplified, and the after-treatment time is shortened; concentrated water is avoided, the energy consumption is reduced, and the yield ofthe product after salt formation reaches 80-85%; the product does not need to be re-crystallized or subjected to activated carbon discoloration, the purity directly reaches 99.5% or higher, and the content of all single impurities is lower than 0.05%; in addition, the use of a type of solvents and reagents containing genotoxicity warning structures is avoided, and totally safe and low-toxicity class-2 and class-3 solvents friendly to the humans and environment are used.

The invention discloses a compound dimetridazole premix for preventing and treating the poultry enterovirus syndrome. The premix is prepared by uniformly mixing the following components in percentage by weight: 10 to 30 percent of dimetridazole, 4 to 10 percent of neomycin sulfate, 2 to 8 percent of decoquinate econazole nitrate, 10 to 30 percent of lysozyme, 0.5 to 5 percent of etamsylate, 3 to 10 percent of lactic acid TMP and the balance of pharmaceutically applicable auxiliary material. According to the invention, the novel high-efficiency anticoccidial drug decoquinate econazole nitrate, the dimetridazole and the neomycin sulfate which have a special curative effect on intestinal infection, the lysozyme with effects of resisting to bacteria, resisting to viruses, diminishing inflammation, relieving pain and repairing intestinal mucosa, the high-efficiency hemostatics etamsylate and the drug synergist are compounded into a compound preparation; and the compound dimetridazole premix has a high-efficiency treatment effect on the poultry enterovirus syndrome. The compound dimetridazole premix has a reasonable and scientific formula, is simple to prepare, has wide application and can be used as a priority drug for preventing and treating the poultry enterovirus syndrome.

The invention relates to a new usage of citric acid and compound citric acid in the field of pharmacy. The product can prevent and control viral diseases and bacterial diseases of livestock and poultry; wherein, the compound citric acid comprises the following components according to weight portion: 93-98 portions of citric acid, 0.5-4 portions of gualfenesin and 1.5-3 portions of etamsylate. Proved by in vivo and vitro experiments, the compound citric acid can play a role in preventing and controlling fowl mycoplasma gallisepticum, avian influenza (H9 subtype), bursal virus disease and otherdiseases, and can effectively kill animal pathogenic bacterias such as cattle colon bacillus, mycoplasma gallisepticum, chicken colibacillosis, etc.

The invention belongs to the technical field of medicine and particularly relates to a medicinal preparation for preventing operative bleeding and a preparation method thereof. The medicinal preparation is prepared from active ingredients etamsylate, sodium metabisulfite, sodium calcium edetate, methylparaben, a pH regulator and water for injection. The phenomenon that bubbles are produced in the filling process of etamsylate injections is avoided, the problem of product yield reduction caused by bubbles is solved, the safety of the injection in clinical application is greatly improved, and the medicinal preparation is simple and easy to operate and facilitates large-scale production.

The invention discloses a biomarker having a high-blood coagulation status and an application of same. In the invention, three different blood coagulation promoting drugs (etamsylate, tranexamic acid and aminocaproic acid) are employed to respectively intervene in blood coagulation status of adult rats, thus successfully obtaining an adult rat acute high-blood coagulation status model; and then change on urine proteomes of the adult rats in intervention groups with different blood coagulation promoting drugs is analyzed; for the first time, the change feature of the urine proteomes under the high-blood coagulation status is systematically researched, and a biomarker, which is related to the high-blood coagulation status, is found in the urine. The invention initially discloses body intervention range and change factors of the high-blood coagulation status, which not only prompt related physiological and pathological mechanisms and the change feature of a signal pathway, but also are applied as an important biomarker in detection and / or diagnosis for related pathological change of the high-blood coagulation status or supply assistant information to the aspect.

The invention discloses a method for producing high-purity etamsylate. The method comprises the following steps: carrying out a sulfonation reaction on hydroquinone serving as an initial material, a sulfonating agent, a dispersing agent and an organic solvent to obtain 2,5-dihydroxybenzenesulfonic acid; cooling the reaction solution to 45-70 DEG C, adding a mixed solution of diethylamine and waterto form a salt, cooling and crystallizing, so as to obtain the etamsylate. According to the reaction system used in the method, the fluidity of the system is improved, and the three-transfer-one-reaction efficiency is improved, so that the conversion rate of the materials is improved by 5-10%; when the system is cooled to 45-70 DEG C after the reaction is ended, the mixed solution of diethylamineand water is directly added into the system, the operation is simplified, and the after-treatment time is shortened; concentrated water is avoided, the energy consumption is reduced, and the yield ofthe product after salt formation reaches 80-85%; the product does not need to be re-crystallized or subjected to activated carbon discoloration, the purity directly reaches 99.5% or higher, and the content of all single impurities is lower than 0.05%; in addition, the use of a type of solvents and reagents containing genotoxicity warning structures is avoided, and totally safe and low-toxicity class-2 and class-3 solvents friendly to the humans and environment are used.

The invention relates to a synthetic method of etamsylate. The synthetic method comprises the following steps of (1) preparation of 2,5-dihydroxybenzenesulfonic acid; (2) preparation of a etamsylate crude product; and (3) purification. Compared with a conventional synthetic process of the etamsylate adopting concentrated sulfuric acid as a sulfonating agent, the synthetic method has the following advantages that the synthetic method employs chlorosulfonic acid as the sulfonating agent, and performs azeotropic dehydration on benzenediol and an organic solvent until anhydrous before sulfonation to ensure that no water is in the reaction system, thereby increasing product yield; hydrogen chloride gas produced during the sulfonation process can be absorbed by water to make hydrochloric acid, thereby decreasing discharge of three wastes (waste gas, waste water and waste residues); and usage amount of the sulfonating agent is decreased during the sulfonation process, so that production cost is reduced.

The invention relates to a uric acid kit for rapidly and simply eliminating drug interference of calcium dobesilate and etamsylate in serum. The uric acid kit is characterized by comprising a reagentR1 and a reagent R2, wherein the reagent R1 comprises a buffer solution, creatinase, creatine oxidase, ascorbic acid oxidase, peroxidase or catalase, serum albumin, a nonionic surfactant, a preservative, a Trinder's reactant A and laccase or metallate; and the reagent R2 comprises a buffer solution, serum albumin, creatininase, a preservative and a Trinder's reactant B. According to the invention,the defect that creatinine determination is inaccurate due to negative deviation caused by the calcium dobesilate and the etamsylate contained in serum samples when creatinine is determined by clinical examination in various hospitals at present is overcome, and the uric acid kit is suitable for detection of serum creatinine by a full-automatic biochemical analyzer.